Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

Acute Lymphocytic Leukemia in the Latin American Population

Elisa Quiroz, MD, Rebecca Nelson, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Thomas Slavin, MD, Guido Marcucci, Eduardo Magalhães Rego, MD PhD, Dan Douer, MD

Blood (2018) 132 (Supplement 1): 5282.

https://doi.org/10.1182/blood-2018-99-120079

Published: 2018

Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2018-99-110537

Published: 2018

Journal Articles

Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos — a Report from a Large Single Institution Cohort in Southern California

Elisa Quiroz, MD, Rebecca Nelson, MD, Vinod A. Pullarkat, MD, Ibrahim Aldoss, Thomas Slavin, MD, Eduardo Magalhães Rego, MD PhD, Guido Marcucci, Dan Douer, MD

Blood (2018) 132 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2018-99-119962

Published: 2018

Journal Articles

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Jae H. Park, MD, Ellen K. Ritchie, MD, Arati V. Rao, Sean Devlin, PhD, Meier Hsu, MS, Talal T Khawaja, B.S., Bridget A O'Donnell, B.S., Maria I Cazacu, B.S., Diane M Stopka, MS, Martin S. Tallman, MD, Dan Douer, MD

Blood (2016) 128 (22): 1629.

https://doi.org/10.1182/blood.V128.22.1629.1629

Published: 2016

Journal Articles

Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program

Jae H. Park, MD, Sean Devlin, PhD, Charles Lynch, Ann Schwartz, Theresa Keegan, PhD MS, Lou Gonsalves, Kim Hermit, MStat, Michael Green, Dan Douer, MD, Martin S. Tallman, MD

Blood (2016) 128 (22): 4008.

https://doi.org/10.1182/blood.V128.22.4008.4008

Published: 2016

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Gary J Schiller, MD, Lloyd E. Damon, MD, Wendy Stock, MD, Steven E Coutre, MD, Pamela Hsu, Lucy Prasad, Dan Douer, MD

Blood (2015) 126 (23): 1291.

https://doi.org/10.1182/blood.V126.23.1291.1291

Published: 2015

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mark D. Minden, MD PhD, Wendy Stock, MD, Howland Crosswell, MD, Robert D Siegel, MD, Patrick Chun, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Dan Douer, MD

Blood (2015) 126 (23): 4866.

https://doi.org/10.1182/blood.V126.23.4866.4866

Published: 2015

Journal Articles

Erwinia Asparaginase Safety and Feasibility during Therapy for Acute Lymphoblastic Leukemia in Adult Patients with Pegaspargase Hypersensitivity or Severe Toxicity

Troy Z Horvat, PharmD, BCOP, Joshua J Pecoraro, PharmD, BCOP, Ryan J Daley, PharmD, BCOP, Larry W Buie, PharmD, BCOP, Dan Douer, MD

Blood (2015) 126 (23): 4915.

https://doi.org/10.1182/blood.V126.23.4915.4915

Published: 2015

Journal Articles

Herpes Zoster Is More Frequent in Patients Receiving Higher Cumulative Doses of Arsenic Trioxide and Is Mitigated By Prophylactic Acyclovir

Jacob Lowell Glass, MD PhD, Ashwin Kishtagari, MD, Dan Douer, MD, Martin S Tallman, MD

Blood (2015) 126 (23): 3752.

https://doi.org/10.1182/blood.V126.23.3752.3752

Published: 2015

Journal Articles

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Samantha N. Reiss, PharmD, Larry W. Buie, PharmD, BCOP, Nelly G. Adel, PharmD, BCOP, BCPS, Debra A. Goldman, MS, Sean Devlin, PhD, Dan Douer, MD

Blood (2015) 126 (23): 3711.

https://doi.org/10.1182/blood.V126.23.3711.3711

Published: 2015

Journal Articles

Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers

Chezi Ganzel, Vikram Mathews, DM, Kamran Alimoghaddam, MD, Ardeshir Ghavamzadeh, MD, Deborah Kuk, ScM, Sean Devlin, PhD, Hailin Wang, Daniel Weisdorf, MD, Dan Douer, MD, Jacob M. Rowe, MD, Arnon Nagler, MD MSc, Mohamad Mohty, Martin S. Tallman, MD, Jordi Estev, Mei-Jie Zhang

Blood (2015) 126 (23): 928.

https://doi.org/10.1182/blood.V126.23.928.928

Published: 2015

Journal Articles

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Chezi Ganzel, Wang Xin Victoria, Adele K. Fielding, MB, BS, PhD, Jacob M. Rowe, MD, Susan M Richards, PhD, Georgina Buck, Rajesh Chopra, PhD, I. Jill Durrant, David Marks, MD PhD, Ian M. Franklin, MD, Andrew K McMilan, Mark R Litzow, MD, Elisabeth Paietta, PhD, Selina Luger, MD, Peter H Wiernik, Dan Douer, MD, Hillard M. Lazarus, MD, Martin S Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2015) 126 (23): 795.

https://doi.org/10.1182/blood.V126.23.795.795

Published: 2015

Journal Articles

A Comprehensive Clinical Next Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies

Blood (2014) 124 (21): 2984.

https://doi.org/10.1182/blood.V124.21.2984.2984

Published: 2014

Journal Articles

Secondary ALL May be Independent of Prior Cytotoxic Therapy

Chezi Ganzel, MD, Sean M. Devlin, PhD, Dan Douer, MD, Eytan M. Stein, Jacob M. Rowe, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3648.

https://doi.org/10.1182/blood.V124.21.3648.3648

Published: 2014

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2014) 124 (21): 5293.

https://doi.org/10.1182/blood.V124.21.5293.5293

Published: 2014

Journal Articles

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MDPhD, Dan Douer, MD, Hervé Dombret, MD, Oliver G. Ottmann, MD, Norbert Vey, MD, Deborah A. Thomas, MD, Lili Zhu, MSc, Fei Huang, PhD, Gaurav Bajaj, PhD, Bruce S. Fischer, MD

Blood (2014) 124 (21): 968.

https://doi.org/10.1182/blood.V124.21.968.968

Published: 2014

Journal Articles

Frequency and Characteristics of Pegaspargase Antibodies in Adults Treated with a Pediatric Acute Lymphoblastic Leukemia Regimen

Patrick W. Burke, MD, Ibrahim Aldoss, MD, Laleh Ramezani, BSc, Vinod Pullarkat, MD, Ann Mohrbacher, MD, Dan Douer, MD

Blood (2014) 124 (21): 936.

https://doi.org/10.1182/blood.V124.21.936.936

Published: 2014

NARROW

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Acute Lymphocytic Leukemia in the Latin American Population

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Clinical, Cytogenetic and Immunophenotype Distribution of Adult Acute Lymphoblastic Leukemia Among Latinos — a Report from a Large Single Institution Cohort in Southern California

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Erwinia Asparaginase Safety and Feasibility during Therapy for Acute Lymphoblastic Leukemia in Adult Patients with Pegaspargase Hypersensitivity or Severe Toxicity

Herpes Zoster Is More Frequent in Patients Receiving Higher Cumulative Doses of Arsenic Trioxide and Is Mitigated By Prophylactic Acyclovir

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

A Comprehensive Clinical Next Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies

Secondary ALL May be Independent of Prior Cytotoxic Therapy

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Frequency and Characteristics of Pegaspargase Antibodies in Adults Treated with a Pediatric Acute Lymphoblastic Leukemia Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only